dextroamphetamine - Profile

What are the generic drug sources for dextroamphetamine and what is the scope of freedom to operate?

Dextroamphetamine is the generic ingredient in seven branded drugs marketed by Noven Pharms Inc, Impax Labs Inc, Able, Actavis Elizabeth, Nesher Pharms, Pharmobedient, Senores Pharms, Specgx Llc, Strides Pharma, Strides Pharma Intl, Teva, Glaxosmithkline, Prasco, Tris Pharma Inc, Ani Pharms, Aurolife Pharma Llc, Avanthi Inc, Azurity, Barr, Epic Pharma Llc, Halsey, Lannett, Mast Mm, Novel Labs Inc, Nuvo Pharm, Purepac Pharm, Sandoz, Vitarine, Winder Labs Llc, Shire, and Ferndale Labs, and is included in forty-one NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dextroamphetamine has twenty-five patent family members in eleven countries.

There is one tentative approval for this compound.

Summary for dextroamphetamine

International Patents:	25
US Patents:	3
Tradenames:	7
Applicants:	31
NDAs:	41
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dextroamphetamine

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for dextroamphetamine

Constraining patent/regulatory exclusivity:

9,456,993

Dosage:

SYSTEM;TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for DEXTROAMPHETAMINE

Applicant	Application No.	Strength	Dosage Form
		25MG	CAPSULE, EXTENDED RELEASE;ORAL
		20MG	CAPSULE, EXTENDED RELEASE;ORAL
		15MG	CAPSULE, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for dextroamphetamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022		RX	Yes	No	9,456,993		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022		RX	Yes	No	11,559,501		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022		RX	Yes	No	9,474,722		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-002	Mar 22, 2022		RX	Yes	No	9,456,993		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-002	Mar 22, 2022		RX	Yes	No	9,474,722		Y
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-002	Mar 22, 2022		RX	Yes	No	11,559,501		Y

Expired US Patents for dextroamphetamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-004	Mar 22, 2022	8,591,941
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-001	Mar 22, 2022	8,591,941
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-003	Mar 22, 2022	8,632,802
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-003	Mar 22, 2022	8,591,941
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-003	Mar 22, 2022	9,034,370
Noven Pharms Inc	XELSTRYM	dextroamphetamine	SYSTEM;TRANSDERMAL	215401-004	Mar 22, 2022	8,632,802

International Patents for dextroamphetamine

Country	Patent Number	Title	Estimated Expiration
Mexico	2016008207	COMPOSICIONES Y METODOS PARA LA ADMINISTRACION TRANSDERMICA DE ANFETAMINA. (COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF AMPHETAMINE.)
European Patent Office	4274555
World Intellectual Property Organization (WIPO)	2014066585
Mexico	376035	COMPOSICIONES Y MÉTODOS PARA LA ADMINISTRACIÓN TRANSDERMICA DE ANFETAMINA. (COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF AMPHETAMINE)
Spain	2621915
Hong Kong	1216503	用於經皮傳遞安非他命的組合物及方法 (COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF AMPHETAMINE)

Investment Scenario and Fundamentals Analysis of Dextroamphetamine

Last updated: February 19, 2026

Does Dextroamphetamine Present a Viable Investment Opportunity?

Dextroamphetamine is a central nervous system stimulant approved primarily for attention deficit hyperactivity disorder (ADHD) and narcolepsy. Its established market presence and patent expirations influence investment considerations. While the drug remains essential, future growth depends on regulatory, market, and competitive dynamics.

Market Overview and Revenue Trajectory

Market Size and Growth

• Global ADHD medication market valued at approximately $17.2 billion in 2022, with dextroamphetamine comprising a significant share.
• Compound annual growth rate (CAGR) estimated at 4% from 2023 to 2028 (Research and Markets, 2023).
• U.S. accounts for roughly 70% of the market, driven by high diagnosis rates and reimbursement structures.

Revenue Breakdown

Revenue Source	Market Share	Notes
Branded formulations	~45%	Includes patents and exclusivity periods (e.g., Vyvanse, Adderall)
Generic formulations	~55%	Expanding with patent expirations (e.g., Adderall in 2023/2024)
Market growth drivers	Diagnosis rates, off-label use, combination therapies

Patent Landscape and Regulatory Environment

Patent Expirations and Generics

• Original patents for dextroamphetamine's formulations expired in the early 2010s.
• Current drugs like Adderall XR face patent expiration around 2023-2024; generic versions significantly eroded previous market exclusivity.
• Pending biosimilar or alternative formulations pose competition risks.

Regulatory Policies and Approvals

• Dextroamphetamine remains a Schedule II controlled substance, limiting prescribing flexibility.
• Ongoing policy discussions regarding opioid and stimulant regulation could influence prescribing practices.
• No recent FDA approvals for new formulations or delivery methods for dextroamphetamine.

Competitive Dynamics

• Major competitors include generic manufacturers, Teva, Mylan, and specialty drug companies.
• Market share shifts toward generics have reduced revenue margins.
• Innovation focuses primarily on abuse-deterrent formulations and delivery mechanisms.

Cost Structure and Pricing Trends

• Average wholesale price (AWP) for generic dextroamphetamine ranges from $0.03 to $0.10 per mg.
• Price erosion is ongoing; price declines of 10-15% annually observed post-patent expiry.
• Cost of goods sold (COGS) for generics is estimated at 15-20% of revenues, driven by manufacturing and distribution.

R&D Pipeline and Future Prospects

• No significant R&D pipeline for novel dextroamphetamine formulations announced.
• Focus on abuse-deterrent delivery systems and extended-release formulations.
• Off-label and combination therapies present alternative growth avenues but face regulatory uncertainty.

Investment Risks and Opportunities

Risks

• Patent expirations accelerate generic competition, reducing revenue.
• Regulatory restrictions on stimulant prescribing or scheduling could limit market size.
• Evolving social and legal perceptions may restrict use or enhance oversight.
• Potential development of non-stimulant alternatives for ADHD treatment.

Opportunities

• Developing abuse-deterrent formulations could sustain premium pricing.
• Expansion into emerging markets with growing ADHD diagnosis.
• License or acquisition of innovative delivery systems or formulations.

Key Financial Metrics and Valuation Indicators

Metric	Estimate	Comments
Market penetration rate	Approximately 6% of diagnosed populations	Growing diagnosis rates, especially in children and adults
EBITDA margins	20-25%, compressed post-generic entry	Margins decline as generic competition intensifies
Investment horizon	3-5 years	Limited near-term growth, with potential for stabilization or decline

Conclusion

Dextroamphetamine's linear revenue prospects are constrained by patent expirations, regulatory pressures, and intense generic competition. Although the market remains sizable, future growth relies on innovation, market expansion, or reformulation strategies. Current valuation models should incorporate declining margins and increased competition risks.

Key Takeaways

• The primary revenue driver is now generics, with prices declining annually post-patent expiry.
• No recent or upcoming FDA approvals for new formulations limit growth potential.
• Market expansion in emerging markets offers growth but involves regulatory and logistical challenges.
• Development of abuse-deterrent formulations offers a potential premium but requires R&D investment.
• Regulatory and social pressures regarding stimulant use may influence long-term viability.

FAQs

1. What is the impact of patent expirations on dextroamphetamine? Patent expirations have led to increased generic competition, reducing prices and market margins significantly.

2. Are there new formulations or delivery systems under development? Current efforts focus on abuse-deterrent and extended-release formulations, but no substantial new approvals are pending.

3. How does regulatory classification affect market outlook? As a Schedule II-controlled substance, prescribing is restricted, and additional regulations can limit market growth.

4. What are the main competitors in this market? Major competitors include generic manufacturers such as Teva and Mylan, alongside branded drugs like Vyvanse and Adderall.

5. Can emerging markets provide growth opportunities? Yes, populations with rising ADHD awareness and diagnosis could expand the market, subject to local regulatory environments.

References

[1] Research and Markets. (2023). Global ADHD medication market analysis.
[2] U.S. Food and Drug Administration. (2022). Approved drug products database.
[3] IQVIA. (2022). U.S. prescription drug market data.